Published in Science on June 08, 1973
Early molecular replication of human immunodeficiency virus type 1 in cultured-blood-derived T helper dendritic cells. J Clin Invest (1993) 1.13
Cell surface changes and Rous sarcoma virus gene expression in synchronized cells. J Cell Biol (1975) 0.98
Rat C6 glioma cell growth is related to glucose transport and metabolism. Biochem J (1996) 0.77
Analysis of the ribonucleic acid of murine leukemia virus. J Virol (1969) 4.32
Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med (1989) 3.03
Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science (1995) 2.16
Temperature-dependent transformation of cells infected with a mutant of Bryan Rous sarcoma virus. J Virol (1972) 2.01
Viral ribonucleic acid polymerase: chick-embryo cells infected with vesicular stomatitis virus or Rous-associated virus. Biochim Biophys Acta (1965) 1.71
Metabolic requirements for infection by Rous sarcoma virus. I. The transient requirement for DNA synthesis. Virology (1966) 1.69
Electron microscopic observations on the ribonucleic acid of murine leukemia virus. J Virol (1969) 1.67
Inhibitors of glycosylation reverse retroviral interference. Virology (1982) 1.64
Control of acute Zollinger-Ellison syndrome with intravenous omeprazole. Lancet (1982) 1.63
Studies on the fixation and development of cellular transformation by Rous sarcoma virus. Virology (1968) 1.57
Induction of mutations in an RNA tumour virus by an analogue of a DNA precursor. Nat New Biol (1971) 1.46
A change in growth potential of cells after conversion by Rous sarcoma virus. J Cell Physiol (1967) 1.45
Characteristics of cores of avian leuko-sarcoma viruses. Virology (1970) 1.36
Accumulation of water during transformation of cells by an avian sarcoma virus. Cell (1974) 1.35
Production of virus by mammalian cells tranformed by Rous sarcoma and murine sarcoma viruses. J Virol (1968) 1.34
Synthesis of the RNA of RNA-containing tumor viruses. I. The interval between synthesis and envelopment. Virology (1970) 1.29
Transformation by murine sarcoma virus: fixation (deoxyribonucleic acid synthesis) and development. J Virol (1968) 1.28
The safety profile of De-Nol. Digestion (1987) 1.26
Glycolysis in chick embryo cell cultures transformed by Rous sarcoma virus. Cancer Res (1968) 1.17
Adenosylhomocysteine hydrolase inhibitors: synthesis of 5'-deoxy-5'-(isobutylthio)-3-deazaadenosine and its effect on Rous sarcoma virus and Gross murine leukemia virus. Biochem Biophys Res Commun (1978) 1.15
Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1. AIDS Res Hum Retroviruses (1997) 1.12
The uptake of nucleosides by cells in culture. I. Inhibition by heterologous nucleosides. Biochim Biophys Acta (1969) 1.04
3-Deazaadenosine, an inhibitor of adenosylhomocysteine hydrolase, inhibits reproduction of Rous sarcoma virus and transformation of chick embryo cells. Virology (1978) 1.03
Discovery and in vitro development of AIDS antiviral drugs as biopharmaceuticals. Adv Pharmacol (1995) 1.02
Metabolic requirements for infection by Rous sarcoma virus. 3. The synthesis on viral DNA. Virology (1972) 0.98
Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins. Antimicrob Agents Chemother (1997) 0.97
Electrophoretic determinations of hyaluronate produced by cells in culture. Biochim Biophys Acta (1972) 0.97
Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors. Antiviral Res (1994) 0.97
Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein. Nat Med (1997) 0.96
Studies on the relationship between glycolysis and (Na+ + K+)-ATPase in cultured cells. Biochim Biophys Acta (1984) 0.95
Configurational variants of oncornavirus RNAs. J Virol (1976) 0.94
Screening of colorectal cancer. Dig Dis Sci (1986) 0.94
A new class of anti-HIV-1 agents targeted toward the nucleocapsid protein NCp7: the 2,2'-dithiobisbenzamides. Bioorg Med Chem (1997) 0.93
Metabolic requirements for infection by Rous sarcoma virus. IV. Virus reproduction and cellular transformation without cellular division. Virology (1972) 0.93
Acute gastroduodenal lesions related to severe sepsis. Surg Gynecol Obstet (1976) 0.93
Acute spontaneously recovering ulcerating colitis (ARUC). Report of 6 cases. Am J Dig Dis (1977) 0.93
[Efficacy of ranitidine and cimetidine in the treatment of gastric or duodenal ulcer resistant to an initial treatment with cimetidine. Multicenter controlled therapeutic trial]. Gastroenterol Clin Biol (1985) 0.92
Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor. J Pharmacol Exp Ther (1996) 0.89
The structure of the RNA of RNA-containing tumor viruses. Curr Top Microbiol Immunol (1970) 0.89
Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide. Antimicrob Agents Chemother (1999) 0.89
[Comparative efficacy of omeprazole and cimetidine in the treatment of duodenal ulcer in the acute stage. A French multicenter, controlled therapeutic trial]. Gastroenterol Clin Biol (1987) 0.88
[Treatment of duodenal and gastric ulcer with cimetidine. A multicenter double-blind trial (author's transl)]. Gastroenterol Clin Biol (1977) 0.88
Design, synthesis, and biological evaluation of cosalane, a novel anti-HIV agent which inhibits multiple features of virus reproduction. J Med Chem (1994) 0.88
Novel sulfonated and phosphonated analogs of distamycin which inhibit the replication of HIV. Antiviral Res (1995) 0.87
[Histological and cytological study of the tumoral and nontumoral endocrine pancreas in the Zollinger-Ellison syndrome]. Rev Int Hepatol (1966) 0.87
The uptake of nucleosides by cells in culture. II. Inhibition by 2-mercapto-1-(beta-4-pyridethyl)benzimidazole. Biochim Biophys Acta (1969) 0.86
Inhibition of human immunodeficiency virus replication by the sulfonated stilbene dye resobene. Antiviral Res (1996) 0.86
Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity. Leukemia (1995) 0.86
Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase. Virology (1995) 0.85
[Collagenous colitis, IgA deficiency, Basedow's disease and atrophic gastritis]. Gastroenterol Clin Biol (1985) 0.85
Sulfonic acid dyes: inhibition of the human immunodeficiency virus and mechanism of action. J Acquir Immune Defic Syndr (1992) 0.85
Evidence for a DNA replicative genome for RNA-containing tumor viruses. Proc Natl Acad Sci U S A (1970) 0.84
Intranuclear degradation of the transformation-inducing protein encoded by avian MC29 virus. J Biol Chem (1986) 0.83
Metabolic requirements for infection by Rous sarcoma virus. II. The participation of cellular DNA. Virology (1966) 0.83
Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program. J Nat Prod (2001) 0.83
[Rat bioassay with urine (PSU) for diagnosis and postoperative follow-up in Zollinger-Ellison syndrome (author's transl)]. Acta Gastroenterol Belg (1973) 0.81
Neural crest cells: temperature-dependent transformation by Rous sarcoma virus. Cell Differ (1979) 0.81
A method for the propagation of large amounts of Rous sarcoma virus. Virology (1968) 0.80
Sodium concentrations affect metabolite uptake and cellular metabolism. J Cell Physiol (1978) 0.79
MC29 virus-coded protein occurs as monomers and dimers in transformed cells. J Virol (1985) 0.79
[Treatment of a case of acute hypercalcemia with furosemide]. Ann Med Interne (Paris) (1971) 0.78
Mass screening for colorectal cancer: statement of the European Group for Colorectal Cancer Screening. Eur J Cancer Prev (1995) 0.78
Uptake of exogenous metabolites by virus-transformed cells: changes induced by temperature and pH. Arch Biochem Biophys (1976) 0.78
Polypeptide composition of cell membranes from chick embryo fibroblasts transformed by rous sarcoma virus. Biochim Biophys Acta (1975) 0.78
Increased glucose uptake capacity of Rous-transformed cells and the relevance of deprivation derepression. Cancer Res (1981) 0.78
Enzyme induction in mammalian cells defective in 28S ribosomal RNA formation. Nature (1976) 0.78
Oncogenes and the mitogenic signal pathway. Important Adv Oncol (1989) 0.77
Transformation of cells by rous sarcoma virus: cytoplasmic vacuolization. J Cell Physiol (1976) 0.77
The efficiency of (Na+ + K+)-ATPase in tumorigenic cells. Biochim Biophys Acta (1983) 0.76
Sodium and rubidium uptake in cells transformed by Rous sarcoma virus. J Cell Physiol (1981) 0.76
Effectiveness of omeprazole in seven patients with Zollinger-Ellison syndrome resistant to histamine H2-receptor antagonists. Dig Dis Sci (1986) 0.76
[Epigastric pain and regurgitation: descriptive epidemiology in a representative sample of the adult population of France]. Gastroenterol Clin Biol (1988) 0.75
Cytoplasmic vacuoles of Rous virus transformed cells are organelles involved in cation uptake. J Gen Virol (1978) 0.75
[Biological tests exploring gastric secretagogic factors during the Zollinger-Ellison syndrome. (Correlation of acid-pepsin and urinary secretagogic capacity)]. Arch Mal Appar Dig Mal Nutr (1965) 0.75
[Histological study of nontumoral islands of Langerhans in Zollinger-Ellison syndrome. Technic and results]. Arch Anat Pathol (Paris) (1965) 0.75
[Chromatographic (Sephadex) isolation of the "PSU factor" in the urine of patients suffering from the Zollinger-Ellison syndrome]. Pathol Biol (1966) 0.75
Circadian rhythmicity of the intestinal transit in rats and its disturbance through experimental hyperthyroidism. Scand J Gastroenterol (1974) 0.75
Hepatic calcification due to Fasciola gigantica. Arch Surg (1974) 0.75
[Insular adenoma with alpha cells. Clinical and biologic data]. Actual Hepatogastroenterol (Paris) (1969) 0.75
[In vitro biosynthesis of the macromolecules of gastric mucosa]. C R Acad Sci Hebd Seances Acad Sci D (1974) 0.75
[Physiology of gastric secretion]. Cah Coll Med Hop Paris (1968) 0.75
[Proceedings: Systemic mastocytosis and the Zollinger-Ellison syndrome]. Schweiz Rundsch Med Prax (1974) 0.75
Biochemical studies on cells infectd with RNA-containing tumor viruses. Bibl Haematol (1968) 0.75
[Electron microscope study of islet cell tumors with alpha cells in the Zollinger-Ellison syndrome]. Actual Hepatogastroenterol (Paris) (1969) 0.75
Physician characteristics. Recruitment of medical students: recent developments in France. J Med Educ (1973) 0.75
The RNA of RNA-containing tumor viruses. Bibl Haematol (1970) 0.75
Letter: Gastric-mucosa injury in sepsis. N Engl J Med (1975) 0.75
Inhibition of development of transformation by Rous sarcoma virus in cultures of high cell density. J Cell Physiol (1974) 0.75
[Digestive localizations of scleroderma and malabsorption]. Sem Hop (1972) 0.75
Discriminative interest of the study of basal acid secretion and pepsin acid correlation in Zollinger-Ellison syndrome and peptic ulcer. Digestion (1973) 0.75
[Chromatographic separation of gastric secretory substances from the urine of Zollinger-Ellison patients]. Clin Chim Acta (1971) 0.75
[The biological syndrome of giant hypertrophic gastritis]. Actual Hepatogastroenterol (Paris) (1968) 0.75
Decreased alkaline phosphatase in cells transformed by rous sarcoma virus. Cancer Res (1978) 0.75
[Action of ICI 50123 polypeptide on human gastric secretion: comparison with spontaneous hypergastrinic conditions]. Arch Fr Mal App Dig (1970) 0.75
[Which, among the currently used drugs, is capable of causing hepatitis?]. Presse Med (1965) 0.75
[How to diagnose the cause and localization of a portal hypertension]. Presse Med (1965) 0.75
[The Zollinger-Ellison syndrome. Clinical, biological, and anatomical study of 10 cases]. Presse Med (1967) 0.75
[Gastro-secretagogue capacity of the urine in the Zollinger-Ellison syndrome]. Rev Int Hepatol (1966) 0.75
[Study of the urinary secretagogue power (U.S.P.) after portacaval anastomosis]. Presse Med (1967) 0.75
A study of the gastro-secretagogue power of urine (P. S. U.) before and after portacaval anastomosis in man. Scand J Gastroenterol (1969) 0.75